Nu Skin Enterprises Financial Statements (NUS)
|
|
|
|
Report date
|
|
|
16.02.2022 |
16.02.2023 |
15.02.2024 |
14.02.2025 |
13.02.2026 |
|
08.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
2 696 |
2 226 |
1 969 |
1 732 |
1 485 |
|
1 441 |
|
Operating Income, bln rub |
|
|
234.0 |
110.8 |
48.3 |
-151.6 |
90.9 |
|
81.5 |
|
EBITDA, bln rub |
? |
|
368.5 |
175.0 |
203.0 |
-78.8 |
143.1 |
|
129.6 |
|
Net profit, bln rub |
? |
|
147.3 |
104.8 |
8.60 |
-146.6 |
160.2 |
|
54.5 |
|
|
OCF, bln rub |
? |
|
141.6 |
108.1 |
118.6 |
111.7 |
80.3 |
|
76.0 |
|
CAPEX, bln rub |
? |
|
68.6 |
59.1 |
58.5 |
41.6 |
34.3 |
|
34.4 |
|
FCF, bln rub |
? |
|
73.0 |
49.0 |
60.1 |
70.2 |
46.0 |
|
41.6 |
|
Dividend payout, bln rub
|
|
|
76.3 |
77.0 |
77.6 |
11.9 |
11.8 |
|
11.7 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
51.8% |
73.5% |
903.1% |
0.00% |
7.39% |
|
21.5% |
|
|
OPEX, bln rub |
|
|
1 786 |
1 484 |
1 309 |
1 333 |
940.5 |
|
917.4 |
|
Cost of production, bln rub |
|
|
675.2 |
630.9 |
611.9 |
550.2 |
453.8 |
|
442.4 |
|
R&D, bln rub |
|
|
27.2 |
0.000 |
22.6 |
13.0 |
0.000 |
|
10.8 |
|
Interest expenses, bln rub |
|
|
11.0 |
21.9 |
25.6 |
26.4 |
13.9 |
|
14.9 |
|
|
Assets, bln rub |
|
|
1 906 |
1 821 |
1 806 |
1 469 |
1 405 |
|
1 377 |
|
Net Assets, bln rub |
? |
|
912.8 |
897.3 |
822.0 |
651.5 |
805.2 |
|
794.1 |
|
Debt, bln rub |
|
|
503.8 |
520.5 |
607.3 |
478.2 |
364.3 |
|
277.6 |
|
Cash, bln rub |
|
|
354.8 |
278.5 |
267.8 |
198.0 |
239.8 |
|
200.4 |
|
Net debt, bln rub |
|
|
149.0 |
242.0 |
339.5 |
280.2 |
124.4 |
|
77.2 |
|
|
Ordinary share price, rub |
|
|
50.8 |
42.2 |
19.4 |
6.89 |
9.62 |
|
5.91 |
|
Number of ordinary shares, mln |
|
|
50.2 |
50.0 |
49.7 |
49.7 |
49.3 |
|
48.2 |
|
|
Market cap, bln rub |
|
|
2 547 |
2 108 |
965 |
342 |
474 |
|
285 |
|
EV, bln rub |
? |
|
2 696 |
2 350 |
1 305 |
622 |
599 |
|
362 |
|
Book value, bln rub |
|
|
629 |
624 |
486 |
494 |
679 |
|
671 |
|
|
EPS, rub |
? |
|
2.93 |
2.10 |
0.17 |
-2.95 |
3.25 |
|
1.13 |
|
FCF/share, rub |
|
|
1.45 |
0.98 |
1.21 |
1.41 |
0.93 |
|
0.86 |
|
BV/share, rub |
|
|
12.5 |
12.5 |
9.77 |
9.94 |
13.8 |
|
13.9 |
|
|
EBITDA margin, % |
? |
|
13.7% |
7.86% |
10.3% |
-4.55% |
9.64% |
|
8.99% |
|
Net margin, % |
? |
|
5.46% |
4.71% |
0.44% |
-8.46% |
10.8% |
|
3.78% |
|
FCF yield, % |
? |
|
2.86% |
2.32% |
6.23% |
20.5% |
9.70% |
|
14.6% |
|
ROE, % |
? |
|
16.1% |
11.7% |
1.05% |
-22.5% |
19.9% |
|
6.87% |
|
ROA, % |
? |
|
7.72% |
5.75% |
0.48% |
-9.98% |
11.4% |
|
3.96% |
|
|
P/E |
? |
|
17.3 |
20.1 |
112.3 |
-2.33 |
2.96 |
|
5.22 |
|
P/FCF |
|
|
34.9 |
43.0 |
16.0 |
4.88 |
10.3 |
|
6.85 |
|
P/S |
? |
|
0.94 |
0.95 |
0.49 |
0.20 |
0.32 |
|
0.20 |
|
P/BV |
? |
|
4.05 |
3.38 |
1.99 |
0.69 |
0.70 |
|
0.42 |
|
EV/EBITDA |
? |
|
7.32 |
13.4 |
6.43 |
-7.90 |
4.18 |
|
2.79 |
|
Debt/EBITDA |
|
|
0.40 |
1.38 |
1.67 |
-3.55 |
0.87 |
|
0.60 |
|
|
R&D/CAPEX, % |
|
|
39.6% |
0.00% |
38.6% |
31.3% |
0.00% |
|
31.4% |
|
|
CAPEX/Revenue, % |
|
|
2.55% |
2.65% |
2.97% |
2.40% |
2.31% |
|
2.39% |
|
| Nu Skin Enterprises shareholders |
